EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim By Ogkologos - September 18, 2025 218 0 Facebook Twitter Google+ Pinterest WhatsApp Vivlipeg is highly similar to the reference product Neulasta, which was authorised in the EU in 2002 Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Cancer Won’t Wait: “I prayed she would see her daughter start... October 11, 2021 New Immunotherapy Option Approved for Cervical Cancer, Rare Lymphoma August 2, 2018 Lymph Node Biopsies Are Unnecessary For Early-Stage Breast Cancer Patients, Study... January 7, 2020 New Task Force Focuses on Quality of Life for AYAs with... August 4, 2021 Load more HOT NEWS FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single... Breast Cancer Centers Rarely Follow National Screening Recommendations, Study Says College Student Rescues Cats Between Classes, Working 2 Jobs, And Planning... FDA Granted Accelerated Approval to Tazemetostat for Follicular Lymphoma
